|Bid||14.02 x 10000|
|Ask||14.65 x 100|
|Day's Range||13.82 - 14.68|
|52 Week Range||8.36 - 27.00|
|Beta (3Y Monthly)||4.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.25|
– EMA Confirmed OMS721 Eligibility for European Centralized Marketing Authorization Application Review –
Omeros Corporation (OMER) today announced that it hired two new senior management team members – Daniel Kirby as vice president and head of commercial and Justin McCue, Ph.D. as vice president of chemistry, manufacturing and controls (CMC). OMIDRIA is the company’s marketed drug and the only product of its kind for cataract and lens replacement surgery.
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Gregory Demopulos has been the CEO of Omeros Corporation (NASDAQ:OMER) since 1994. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we’ll Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 8) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) AstraZeneca ...
Omeros Corporation (OMER) (“Omeros”) today announced the pricing of an offering of $210 million aggregate principal amount of its 6.25% Convertible Senior Notes due 2023 (the “Notes”) in a private offering (the “Offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the “Securities Act”). Omeros has granted the initial purchasers of the Notes an option to purchase up to an additional $40 million aggregate principal amount of the Notes on the same terms and conditions referenced above. The Notes will be senior unsecured obligations of Omeros and interest will be payable semi-annually in arrears at a rate of 6.25% per annum.
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual ...
Omeros (OMER) delivered earnings and revenue surprises of 1.39% and 50.34%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Seattle-based company said it had a loss of 81 cents. Losses, adjusted for non-recurring costs, were 71 cents per share. The drug developer posted revenue of $4.6 million in the ...
SEATTLE, Nov. 8, 2018 /PRNewswire/ -- Omeros Corporation (OMER) ("Omeros") today announced its intention to offer, subject to market and other conditions, $210 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in a private offering (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the "Securities Act"). Omeros also intends to grant the initial purchaser of the Notes a 30-day option to purchase up to an additional $40 million aggregate principal amount of the Notes, for a total potential offering size of $250 million. The Notes will mature on November 15, 2023, unless earlier converted, repurchased or redeemed in accordance with their terms, and will be convertible, subject to the satisfaction of certain conditions, into cash, shares of Omeros' common stock or a combination thereof as elected by Omeros in its sole discretion.
Omeros Corporation (OMER) today announced that the company will issue its third quarter 2018 financial results for the period ended September 30, 2018, on Friday, November 9, 2018, before the market opens. In addition, Omeros has a diverse group of preclinical programs and a proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and corresponding compounds, a number of which are in preclinical development.
Omeros Corporation (OMER) today announced that OMS721 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / October 2, 2018 / U.S. equities were mixed on Monday after the U.S. and Canada agreed to revise the current North American Free Trade Agreement. The Dow Jones Industrial Average ...
Omeros Corp. shares dropped nearly 45% in Monday afternoon trade after the company released results from a phase 2 trial testing its OMS721 therapy in a progressive kidney disease called immunoglobulin A (IgA) nephropathy. The trial measured reductions in protein levels in patients' urine, called proteinuria, the "most reliable prognostic factor for loss of kidney function" in this disease. The most recent results were based on a group of nine patients who had not received corticosteroid treatment and had a high risk of disease progression, or "a difficult-to-treat population," according to Jonathan Barratt, professor of renal medicine at the University of Leicester. Of those individuals, median reductions in proteinuria after 12 weeks of therapy were very similar: 18.4% for OMS721 and 18% for placebo groups. Omeros continued to treat patients after 12 weeks, and of those eight patients, median proteinuria reductions were nearly 56%, the company said. Four individuals on Omeros' therapy in the dosing-extension period had reductions of between 53.9% and 67.8%, it said. The company continues to treat patients in this dosing-extension period and plans to present additional data at a future medical meeting. IgA nephropathy's most common symptoms are blood in the urine and foamy urine, according to the American Kidney Foundation, and doctors try to slow down the disease's characteristic kidney damage. It affects an estimated 1 in 1,400 individuals in the U.S. and currently has no approved treatments, according to Omeros. Omeros shares have dropped nearly 26% over the last three months, compared with a 7.7% rise in the S&P 500 and a nearly 10% rise in the Dow Jones Industrial Average .
Omeros Corporation (OMER) today announced positive data from the company’s ongoing Phase 2 clinical trial of OMS721 for the treatment of renal diseases. The data are from study patients with immunoglobulin A (IgA) nephropathy, a progressively worsening kidney disease and the most common glomerulonephritis worldwide, responsible for 10 percent of all people on dialysis globally. Patients in this cohort had IgA nephropathy with high risk of progression but none received corticosteroid treatment immediately prior to or during the study – different than the cohort reported last year in which all patients initiated the study while on steroid therapy.
Todd Shriber’s pick for the contest is the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO). The ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO), my choice for the InvestorPlace Best ETFs for 2018 competition, is enduring its worst quarter of 2018. With just a few trading days left in the third quarter, SBIO is sporting a quarter-to-date loss of 0.2%.
Omeros Corporation , today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2018 Cantor Global Healthcare Conference in New York next week.